



## Lenvima<sup>®</sup> (lenvatinib) – New warning

- On June 6, 2018, the FDA approved an update to the *Warnings and Precautions* section of the [Lenvima \(lenvatinib\)](#) drug label regarding wound healing complications.
- Lenvima is approved to treat patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer; and in combination with [everolimus](#) for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.
- Wound healing complications, including fistula formation and wound dehiscence, can occur with Lenvima.
  - Lenvima should be withheld for at least 6 days prior to scheduled surgery.
  - Lenvima may be resumed after surgery based on clinical judgment of adequate wound healing.
  - Lenvima should be permanently discontinued in patients with wound healing complications.



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.